论文部分内容阅读
目的:观察含ω-3多不饱和脂肪酸(polyunsaturated fatty acids，PUFAs)的肠内营养对胃癌患者术后营养状况及生活质量的影响。方法:选择门诊确诊为单纯性局部进展期胃癌并拟行远端胃癌D2根治术和常规化疗的患者60例，随机分为ω-3 PUFAs肠内营养干预组(ω-3组)和常规肠内营养干预组(对照组)。两组均在术后启动肠内营养时开始干预，持续3个月，比较两组患者干预前和干预结束时的营养状况、炎症指标、生活质量评分等。结果:共有52例患者完成研究，ω-3组25例，对照组27例，干预后ω-3组患者血液中ω-3 PUFAs、ω-6 PUFAs浓度较对照组和干预前均显著升高(n P<0.01)，C反应蛋白显著降低(n P<0.05)，维生素Bn 12浓度较对照组显著升高(n P<0.05)，体重、体重指数显著高于对照组(n P<0.05)，能量和蛋白质摄入、生活质量评分均优于对照组(n P<0.01)。n 结论:胃癌患者术后恢复期进行富含ω-3 PUFAs的肠内营养治疗，有助于改善其营养状况，降低炎症反应，提高生活质量。“,”Objective:To observe the effect of enteral nutrition containing ω-3 polyunsaturated fatty acids(PUFAs) on the nutritional status and quality of life of patients after radical surgery.Methods:A total of 60 locally advanced gastric cancer patients undergoing D2 radical surgery and standard chemotherapy were selected and randomly divided into ω-3 group (receiving enteral nutrition containing ω-3 PUFAs) and control group (receiving routine enteral nutrition intervention). The intervention was initiated at the time of postoperative enteral nutrition initiation and lasted for 3 months. Then we compared the nutritional status, inflammation index, quality of life scores before and after the intervention between the two groups.Results:52 patients completed the trial, including 25 in the ω-3 group and 27 in the control group. After intervention, the blood ω-3 and ω-6 PUFAs levels of the ω-3 group were significantly higher and the C-reactive protein were reduced than those of the control group and before intervention ( n P<0.01), and the concentration of vitamin Bn 12 of the ω-3 group was significantly higher than that of the control group ( n P<0.05). Body weight and body mass index of the ω-3 group were significantly higher than those of the control group(n P<0.05), and the energy and protein intake, the quality of life scores of the ω-3 group were better than those of the control group (n P<0.01).n Conclusion:Enteral nutrition support containing ω-3 PUFAs is helpful to improve the nutritional status, reduce the inflammatory response and improve the quality of life of patients with gastric cancer in the recovery period.